Drug with Active Substance Nusinersen 12 Mg Tender - 142540333

Procurement Summary

Country: Slovakia

Summary: Drug with Active Substance Nusinersen 12 Mg, Solution for Injection

Deadline: 10 Jul 2026

Posting Date: 03 Jun 2026

Other Information

Notice Type: Tender

TOT Ref.No.: 142540333

Document Ref. No.: 379240-2026

Competition: ICB

Financier: Self Financed

Purchaser Ownership: Public

Tender Value: EUR 3892818.4

CPV Classification

33632000 - Medicinal products for the musculo-skeletal system

Purchaser's Detail

Name: Login to see tender_details

Address: Login to see tender_details

Email: Login to see tender_details

Login to see details

Tender Details

DRUG WITH ACTIVE SUBSTANCE NUSINERSEN 12 MG, SOLUTION FOR INJECTION The subject of the contract is the medicine NUSINERSEN 12 MG INJECTION SOLUTION Supplement: salt inj 5 ml/12 mg (drug.inj.glass) Administration: intrathecal use One 5 ml vial contains nusinersen sodium, which is equivalent to 12 mg of nusinersen. One ml contains 2.4 mg of nusinersen. Nusinersen is an antisense oligonucleotide (antisense oligonucleotide, ASO) that increases the proportion of exon 7 inclusion in messenger ribonucleic acid transcripts acid, mRNA) for SMN2 (survival motor neuron 2, SMN2) by binding to the intronic splice silencing site (ISS-N1) located in intron 7 of the SMN2 pre-messenger ribonucleic acid (pre-mRNA) for SMN2. ASO displaces with this binding splicing factors that normally suppress splicing. Displacement of these factors results in retention of exon 7 in SMN2 mRNA, and therefore when SMN2 mRNA is formed, it can be transcribed into functional full-length SMN protein. Medicine with the active substance Nusinersen is indicated for the treatment of 5q spinal muscular atrophy. Treatment with this medicine should only be started by a doctor with experience in spinal muscular atrophy (SMA). The decision to treat must be based on an individualized professional evaluation of expectations the benefits of treatment for a specific patient balanced against the potential risk of drug treatment. In patients with severe hypotension and resp...
Document Type: Contract Notice Reference Number: 62-2026 Contract Type: supplies Estimated Value: 3892818.4 - EUR Authority Type: body-pl-cga Doc Title: DRUG WITH ACTIVE SUBSTANCE NUSINERSEN 12 MG, SOLUTION FOR INJECTION Dispatch Date: 2026-06-02 Publish Date: 2026-06-03 Submission Date: 2026-07-10

Documents

 Tender Notice